ASP8825 - A Study to Investigate the Food Effect on the Pharmacokinetics of ASP8825

Inclusion criteria

• Body weight: ≥50.0 kg and <80.0 kg
• Body mass index BMI: ≥17.6 and <26.4 [BMI= Body weight (kg)/(Height (m))2]

Exclusion criteria

• Subjects who received any study drugs in other clinical trials or post-marketing studies within 120 days before screening
• Subjects who received or are scheduled to receive medications (including over-the-counter [OTC] drugs) within seven days before the hospital admission day of period 1.
• Subjects who deviate from the normal range of blood pressure, pulse rate, body temperature and standard 12-lead ECG at screening or the hospital admission day of period 1
• Subjects who meet any of the criteria for laboratory tests at screening or the hospital admission day of period 1. Normal ranges of each test specified at the study site or the test/assay organization will be used as the normal ranges in this study.
• Subjects with a complication of drug allergies
• Subjects who developed upper gastrointestinal symptoms (e.g., nausea, vomiting, and stomachache) within seven days before the hospital admission day of period 1
• Subjects with a complication or history of hepatic disease (hepatitis viral and drug-induced liver injury, etc.)
• Subjects with a complication or history of heart disease (cardiac failure congestive, angina pectoris and arrhythmia requiring treatments, etc.)
• Subjects with a complication or history of respiratory disease (severe asthma bronchial and bronchitis chronic, etc.) (except for a history of non-severe infantile asthma)
• Subjects with a complication or history of alimentary disease (severe peptic ulcer, reflux esophagitis, etc.) (except for a history of appendicitis)
• Subjects with a complication or history of renal disease (acute kidney injury, glomerulonephritis, nephritis interstitial, etc.) (except for a history of calculus)
• Subjects with a complication or history of cerebrovascular disorder (cerebral infarction, etc.)
• Subjects with a complication or history of malignant tumor
• Subjects who have a habit of excessive alcohol drinking or smoking
• Subjects who previously received administration of ASP8825